>1,000-fold multiparameter optimisation of an enzyme inhibitor to generate a best-in-class antibody. First human dosed within 18 months of programme initiation. Now in Phase 3.

Many cancer drivers are intracellular, beyond conventional antibodies, but HLA class I displays their fragments as peptide-HLA complexes. The challenge is discriminating a mutant pHLA from its wild-type form, often one amino acid apart, since any cross-reactive clone becomes on-target toxicity. FairJourney Bio used counter-selection across four naïve human libraries to recover 53 mutant-specific Fvs and a lead T-cell engager at 2.97 nM.

Biologics for companion animals are advancing, but the reporter cell lines needed to characterise them are often not commercially available, with little supporting literature. FairJourney Bio engineered two custom reporter cell lines, for a dual-chain receptor and a GPCR, to evaluate blocking antibodies in animal health. Both reached IND-ready status with validated IC50 readouts, in under 3.5 months from vector design to clone delivery.